Grant: CCI Applied Research and Development Grants

This initiative builds upon an established collaboration between DermBIOme and TransBIOTech. DermBIOme has developed a triterpenoid analogue name PB-207 that displays anti-inflammatory effects as well as microbiota-modulating properties with favourable pharmacological properties for clinical development. Following in cellulo and in vivo pharmacology validation, the compound demonstrated efficacy in longevity studies that the company now wants to explore into deep to better position the preclinical development in order to move forward into clinical trials. The primary objectives of this ARD project are to evaluate PB-207 efficacy into diverse aspects of aging in a murine preclinical model, including inflammation-related aspects and cognitive functions. A metabolic syndrome mimicking model in aged mice will also establish the effect of diabetes, an age-associated burden in the entire population. Taken together, the conduct of these studies will provide valuable data that will strengthen the position of the company and its product toward IND-enabling preclinical studies.